Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T14:13:03.694Z Has data issue: false hasContentIssue false
  • English
  • Français

The Use of Disease-Modifying Agents in Multiple Sclerosis - by the Canadian Network of MS Clinics

Published online by Cambridge University Press:  02 December 2014

Paul O’Connor
Paul O’Connor*
Affiliation:
Virginia Devonshire for the Canadian Network of MS Clinics
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Guidelines
Information
Canadian Journal of Neurological Sciences , Volume 35 , Issue 2 , May 2008 , pp. 127 - 129
Copyright
Copyright © The Canadian Journal of Neurological 2008

References

1. Polman, CH, Reingold, SC, Edan, G, Filippi, M, Hartung, HP, Kappos, L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005; 58(6):840–6.CrossRefGoogle Scholar
2. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993; 43:655–61.Google Scholar
3. Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996; 39:285–94.CrossRefGoogle Scholar
4. PRISMS Study Group. Randomized double-blind placebocontrolled study of interferon [beta]-1a in relapsing/remitting multiple sclerosis. Lancet. 1998; 352:1498–504.Google Scholar
5. Johnson, K, Brooks, B, Cohen, JA, Ford, CC, Goldstein, R, Lisak, RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995; 45:1268–76.Google Scholar
6. Polman, CH, O’Connor, PW, Haverdova, E, Hutchinson, M, Kappos, L, Miller, DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; Mar 2; 354(9):899–910.CrossRefGoogle ScholarPubMed
7. Health Canada-Product Monograph 2006.Google Scholar
8. Jacobs, LD, Beck, RW, Simon, JH, Kinkel, RP, Brownscheidle, CM, Murray, TJ, et al. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000; 343:898–904.CrossRefGoogle Scholar
9. Comi, G, Filippi, M, Barkhof, F, Durelli, L, Edan, G, Fernandez, O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001; 357: 1576–82.Google Scholar
10. Kappos, L, Polman, CH, Freedman, MS, Edan, G, Hartung, HP, Miller, DH, et al. Treatment with interferon beta-lb delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 10; 67(7): 1242–9.Google Scholar
11. Hartung, HP, Gonsette, R, Konig, N, Kwiecinski, H, Guseo, A, Morrissey, SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet. 2002; 360(9350):2018–25.Google Scholar
12. Goodin, DS, Arnason, BG, Coyle, PK, Frohman, EM, Paty, DW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003; 61(10): 1332–8.CrossRefGoogle Scholar
13. Goodin, DS, Frohman, EM, Hurwitz, B, O’Connor, PW, Oger, JJ, Reder, AT, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007; 68(13):977–84.Google Scholar